GKOS News and Press, Glaukos Corporation From 01/09/24

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced its preliminary, unaudited net sales for the fourth quarter and full year ended December ...

2024-01-09 04:03:33 ET Summary Glaukos Corporation's sales growth remains a key indicator for investors, with a 10% increase in Q3 leading to a 50% increase in stock value over the past 14 months. Long-term trends show that the stock has remained flat over the past 5 years despite...

2023-12-28 10:11:14 ET More on Sight Sciences Sight Sciences, Inc. (SGHT) Q3 2023 Earnings Call Transcript Sight Sciences climbs after update on Medicare coverage for glaucoma procedure Sight Sciences spikes after insider purchases Seeking Alpha’s Quan...

2023-12-26 12:21:27 ET More on Sight Sciences Sight Sciences, Inc. (SGHT) Q3 2023 Earnings Call Transcript Sight Sciences spikes after insider purchases Sight Sciences slumps amid risk for Medicare coverage for glaucoma procedure Seeking Alpha’s Quant ...

2023-12-22 17:51:02 ET More on Glaukos Glaukos Corporation (GKOS) Q3 2023 Earnings Call Transcript BTIG makes top medtech stock picks for 2024, sees sector stabilizing Glaukos stock jumps 15% on FDA approval of glaucoma drug Seeking Alpha’s Quant Ratin...

2023-12-21 06:45:03 ET Wells Fargo analyst issues BUY recommendation for GKOS on December 21, 2023 07:00AM ET. The previous analyst recommendation was Buy. GKOS was trading at $79.6 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ...

2023-12-17 17:48:14 ET More on Abbott Laboratories, Glaukos, etc. Abbott Laboratories: A 'Must-Have' In A Defensive Dividend Growth Portfolio Zimmer Biomet: Still Many Questions After A Solid Year So Far Abbott Laboratories: One Of The Safest Dividend Growth Stocks O...

2023-12-15 13:45:01 ET William Blair analyst issues OUTPERFORM recommendation for GKOS on December 15, 2023 01:49PM ET. The previous analyst recommendation was Outperform. GKOS was trading at $79.83 at issue of the analyst recommendation. The overall analyst consensus : ...

2023-12-14 10:47:34 ET More on Glaukos Glaukos Corporation (GKOS) Q3 2023 Earnings Call Transcript Truist starts Glaukos at buy, cites glaucoma market opportunity Sight Sciences slumps amid risk for Medicare coverage for glaucoma procedure Seeking Alphaȁ...

Revolutionary, micro-invasive, injectable treatment for the full range of glaucoma disease severity iDose TR was designed to usher in a new era of interventional glaucoma by enabling a proactive approach with a safe, effective, and durable therapy for patients in need FDA approval...